BridgeBio Pharma, Inc.
NASDAQ:BBIO
25.2 (USD) • At close November 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | BridgeBio Pharma, Inc. |
Symbool | BBIO |
Munteenheid | USD |
Prijs | 25.2 |
Beurswaarde | 4,738,431,600 |
Dividendpercentage | 0% |
52-weken bereik | 21.62 - 44.32 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Neil Kumar Ph.D. |
Website | https://www.bridgebio.com |
An error occurred while fetching data.
Over BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)